- This event has passed.
Texas Health CoLab Learning Series
July 30 @ 3:00 pm - 4:00 pm
Learn what corporate venture arms look for when investing in digital and therapeutic interventions
The presentation will explore:
• Early considerations – What will corporate venture look for?
• Assessing alignment – Is this smart money?
• Digital vs. Therapeutic investment evaluation
• What does it take to close a deal?
About the Speaker: Gladys Nunez, Principal Amgen Ventures, joined Amgen in 1997 and leads investment diligence for the corporate venture investment strategy supporting R&D innovation goals. She also runs the Amgen Ventures R&D Seed Fund established in 2018. As part of her portfolio management activities Nunez is the board observer on Obsidian Therapeutics, Quralis, Caraway Therapeutics, Celsius, Ribometrix, and Akili Interactive. Prior to joining Amgen Ventures in 2014, Nunez spent 12 years in Amgen’s Technology Licensing Business Development group prospecting and negotiating external alliances. Nunez also worked 7 years in R&D, and holds an MSc in Biochemical Pharmacology from the University of Southampton in England, and BSc from Marist College.